Previous 10 | Next 10 |
home / stock / crl / crl articles
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigat...
Charles River Laboratories International Inc (NYSE:CRL) reported fourth-quarter 2023 revenue of $1.01 billion, a decrease of 7.9% Y/Y, beating...
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and...
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Dollar General Corporation Johnson Fistel, LLP is investigating potential claims on behalf of Doll...
Disclosed in a recent SEC filing on January 31, Foster, Chairman at Charles River (NYSE:CRL), made a noteworthy transaction involving the exercise ...
SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Dollar General Corporation Johnson Fistel, LLP is investigating potential claims on behalf of Doll...
SAN DIEGO, Nov. 17, 2023 (GLOBE NEWSWIRE) -- FedEx Corporation (NYSE:FDX) Johnson Fistel, LLP is investigating potential claims on behalf of Fe...
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make...
Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating ...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good...
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract...